BioSpace News Archive

Nabriva Therapeutics plc announced the appointment of Dr. Christine Guico-Pabia, M.D., MBA, MPH as Chief Medical Officer (CMO) effective October 1, 2021.

Cogent Biosciences, Inc. today announced that the Company will present preclinical data on bezuclastinib at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics held October 7-10, 2021.

Compass Therapeutics, Inc. and ABL Bio, Inc. announced today that the Phase 1 monotherapy dose escalation and expansion study data for CTX-009 (ABL001/ES104), a bispecific dual angiogenesis inhibitor targeting DLL4 and VEGF-A, has been selected for an oral plenary presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, being held virtually on October 7-10, 2021.

Cybin Inc. is pleased to announce: the addition of Dr. Amir Inamdar as its Chief Medical Officer for its European Operations, the addition of Dr. Geoff Varty as its new Head of Research and Development.

- Dystrophin Restoration of 90% of Wild-Type Levels Observed in the Diaphragm and 78% in the Heart with ~80% Dystrophin-Positive Fibers After a Single Dose in mdx Mouse Model

Agenus Inc. (NASDAQ: AGEN), today announced acceptance of its abstract describing updated Phase 1 clinical trial results for AGEN1181 (Fc-enhanced anti-CTLA-4) alone and in combination with balstilimab (anti-PD-1) at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting.

Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, announced positive results from its Phase 1 clinical trial of AZP-3601, a potential treatment for hypoparathyroidism, at the American Society for Bone and Mineral Research 2021 Annual Meeting.

Aravive, Inc. (Nasdaq: ARAV), today announced that new preliminary safety, pharmacokinetic, pharmacodynamic, and clinical activity data from the Phase 1b portion of its open-label Phase 1b/2 trial evaluating AVB-500 in combination with cabozantinib in patients with clear cell renal cell carcinoma (ccRCC) will be presented at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting.

Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, will present an oral presentation at the 2021 European Society for Gene and Cell Therapy (ESGCT) Congress being held in a virtual format from October 19-22, 2021, and two posters at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting.

Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that three posters featuring preclinical data from its engEx™ Platform programs will be presented during the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2021).